Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation

J Vet Med Sci. 2015 Nov;77(11):1535-9. doi: 10.1292/jvms.15-0096. Epub 2015 Jun 12.

Abstract

A 13-year-old spayed mixed-breed dog was diagnosed with a gastrointestinal stromal tumor (GIST) after histopathological examination of an abdominal mass. Five months after surgical resection of the tumor, we detected the recurrence of GIST with multiple disseminated abdominal lesions. A sequence analysis of cDNA obtained from a biopsy of the recurrent tumors revealed a mutation within exon 9 of the c-kit gene (1523A>T, Asn(508)Ile), which has been shown to cause ligand-independent phosphorylation of the KIT protein in GISTs and canine mast cell tumors (MCTs). Upon detection of the recurrent tumors, we initiated treatment with imatinib mesylate (10 mg/kg, q 24 hr). After 2 months, the dog achieved complete remission. Our findings indicate that canine GIST, and possibly MCT, may be responsive to molecular-targeted therapy.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • DNA, Complementary
  • Dog Diseases / drug therapy*
  • Dog Diseases / metabolism
  • Dog Diseases / surgery
  • Dogs
  • Female
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / metabolism
  • Gastrointestinal Neoplasms / veterinary*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / surgery
  • Gastrointestinal Stromal Tumors / veterinary*
  • Gene Expression Regulation
  • Imatinib Mesylate / therapeutic use*
  • Mutation
  • Proto-Oncogene Proteins c-kit / genetics
  • Proto-Oncogene Proteins c-kit / metabolism*

Substances

  • Antineoplastic Agents
  • DNA, Complementary
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit